

IN THE CLAIMS

In accordance with CFR 1.121, please amend claim 25 as follows:

25. (Amended) A pharmaceutical composition which comprises an effective amount of a gamma common chain blocking agent wherein the agent is a monoclonal antibody selected from the group consisting of:

- (a) a monoclonal antibody that cross competes with monoclonal antibody CP.B8 produced by hybridoma cell line ATCC No. HB-12107 for binding to gc chain, and also cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said CP.B8;
- (b) a monoclonal antibody that cross competes with monoclonal antibody CQ.C11 produced by hybridoma cell line ATCC No. HB-12105 for binding to gc chain, and also cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said CQ.C11;
- (c) a monoclonal antibody that cross competes with monoclonal antibody AF.F4 produced by hybridoma cell line ATCC No. HB-12104 for binding to gc chain, and cross competes Fab, F(ab')₂, and Fv fragments and conjugates of said AF.F4; and
- (d) a monoclonal antibody that cross competes with the monoclonal antibody AE.C9 produced by hybridoma cell line ATCC No. HB-12106 for binding to gc chain, and cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said AE.C9.

REMARKS

Claim Rejections – 35 USC § 112, first paragraph

The Examiner has rejected newly amended claim 25 under 35 USC § 112, first paragraph. In accordance with 37 CFR sections 1.801 through 1.809, Applicants submit herewith a Declaration by the attorney of record stating that the ATCC deposits have been accepted by an International Depository Authority under the provisions of the Budapest Treaty. Accordingly, Applicants submit that this rejection has been obviated and request withdrawal of the rejection.

Claim Rejections – 35 USC § 112, second paragraph

The Examiner has rejected amended claim 25 under 35 USC § 112, second paragraph. Applicants have amended claim 25. Support for the amendment can be found in the